Travere Therapeutics reported third‑quarter 2025 results, posting a net income of $25.7 million and GAAP earnings per share of $0.29, compared with a net loss of $54.8 million and a loss per share of $0.70 in the same quarter of 2024.
Revenue for the quarter rose to $164.9 million, a 160 % year‑over‑year increase and a 44 % sequential rise from $114.4 million in Q2 2025. The growth was driven by U.S. net product sales of the flagship drug FILSPARI, which reached $90.9 million, up 155 % from $36.8 million in Q3 2024.
The company also recognized a $40 million market‑access milestone payment from CSL Vifor and $9.3 million in non‑cash license revenue from its partnership with Renalys, contributing to the turnaround in profitability.
Management highlighted the impact of the August 2025 REMS modification for FILSPARI, which simplified access and monitoring, and the inclusion of the drug in the updated KDIGO guidelines for early, first‑line treatment of IgA nephropathy, both of which helped expand prescriber confidence.
Travere’s non‑GAAP adjusted earnings per share were $0.59, and the company beat consensus estimates of a loss per share, with analysts expecting a loss of $0.29 to $0.62.
No new guidance was issued for the next quarter, but the company reiterated its focus on scaling FILSPARI commercialization and advancing its pegtibatinase program, with the HARMONY study slated to restart in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.